Australia's most trusted
source of pharma news
Wednesday, 02 July 2025
Posted 1 July, 2025 AM
Moderna plans to file submissions with regulators for its mRNA seasonal flu vaccine after announcing positive results from a Phase 3 efficacy study which showed the shot achieved superiority over the competition.
Overnight the company released trial results which showed its mRNA1010 standard flu vaccine "achieved the most stringent superiority criterion prespecified in the protocol" with a relative vaccine efficacy (rVE) of 26.6 per cent.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.